Dutch researchers argued for incorporating whole-genome sequencing into routine cancer care, using real-world analysis to quantify actionable findings beyond standard targeted approaches. In a Nature Medicine study, they reported that 73% of patients had at least one clinically actionable biomarker and that WGS yielded clinically relevant results in 41% of cases, including targeted biomarkers, pathogenic germline variants, and diagnosis refinement. The study compared WGS outcomes with commonly used panel approaches, including Thermo Fisher’s 50-gene AmpliSeq Cancer Hotspot and Illumina’s TruSight Oncology 500. It used data from 888 patients treated at the Netherlands Cancer Institute in Amsterdam, with sequencing performed at the Hartwig Medical Foundation. For biotech diagnostics and oncology pipelines, the finding strengthens the case for broader WGS adoption—though uptake will still depend on cost, workflow integration, and reimbursement decisions.